USFDA completes PAI, GMP audit at Granules India’s Unit IV facility

01 Jul 2023 Evaluate

The United States Food and Drug Administration (USFDA) has successfully completed Pre-Approval Inspection (PAI) and GMP audit at Granules India’s Unit IV facility located at Visakhapatnam, Andhra Pradesh, India, with zero 483 observations. The inspection conducted from June 26, 2023 to June 30, 2023. Unit IV facility located at Visakhapatnam manufactures Active Pharmaceutical Ingredients (API).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

585.50 -7.40 (-1.25%)
27-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1861.70
Dr. Reddys Lab 1389.35
Cipla 1506.15
Lupin 2228.00
Zydus Lifesciences 972.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.